Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Fed comments provide support ahead of BoE, ECB

Thu, 07th Mar 2013 08:43

The FTSE 100 held on to recent gains on Thursday morning ahead of central-bank policy decisions in the UK and Europe, as comments from the Federal Reserve provided some support.According to the Fed's Beige Book released last night, the US economy expanded at a "modest to moderate pace" at the start of 2013 due to strong car sales, hiring gains and a recovery in the housing sector.The UK benchmark index surged to levels not seen since late 2007 earlier this week a better-than-expected reading of US services activity and a pledge by China to hit its growth targets this year boosted markets.It appears that markets were pausing for breath today ahead of policy decisions from the Bank of England and European Central Bank expected after midday. Speculation has increased over the last month about changes to policy from both sides so investors are likely to sit on their hands and refrain from taking risk until someone makes a move.Overnight, the Bank of Japan voted to keep interest rates and its asset purchase programme unchanged, a decision that was widely expected given the Bank's recent aggressive easing.FTSE 100: Aviva plummets after 'rebasing' diviInsurance giant Aviva was forced to slash to dividend after swinging into the red in 2012, after taking a 3.3bn-pound write-down on a disposal in the US. Aviva also said that its overall situation does not warrant bonuses for executive directors for 2012 or pay rises for 2013. Shares dropped sharply early on.Heading the other way was temporary power and temperature control provider Aggreko after posting a strong performance with trading profit up 13% last year.Insurance provider Standard Life gained after unveiling a windfall dividend worth £302m after delivering substantial growth in profits in 2012 underpinned by strong performance in the UK.British asset management firm Schroders was higher after saying that assets under management (AuM) reached record levels in spite of choppy markets and falling profits.Pharma giant GlaxoSmithKline rose after announcing positive data from a drug study through ViiV Healthcare, a global specialist HIV company set up by GSK in 2009.FTSE 250: National Express dropsTransport group National Express was a heavy faller after reports yesterday said that US investor Elliot Advisors plans to sell over 50m worth of shares, equal to a 9.9% stake.Engineering firm Spirax-Sarco was in demand after proposing a special dividend of 100p per share in addition to an 8.0% rise in the full-year payout, after a 2.0% rise in revenue in 2012.FTSE 100 - RisersAggreko (AGK) 1,932.00p +9.90%IMI (IMI) 1,328.00p +5.23%Admiral Group (ADM) 1,362.00p +2.10%Standard Life (SL.) 380.30p +1.63%Unilever (ULVR) 2,721.00p +1.45%Barclays (BARC) 306.50p +1.44%Reckitt Benckiser Group (RB.) 4,568.00p +1.15%Antofagasta (ANTO) 1,075.00p +1.03%Kazakhmys (KAZ) 560.50p +0.99%Schroders (SDR) 2,056.00p +0.98%FTSE 100 - FallersAviva (AV.) 310.80p -13.62%Melrose Industries (MRO) 260.10p -2.62%Polymetal International (POLY) 958.00p -1.79%British Sky Broadcasting Group (BSY) 874.00p -1.63%Morrison (Wm) Supermarkets (MRW) 259.20p -1.52%Lloyds Banking Group (LLOY) 50.30p -1.41%Serco Group (SRP) 621.50p -0.88%Vodafone Group (VOD) 178.60p -0.78%Legal & General Group (LGEN) 164.90p -0.66%Old Mutual (OML) 208.80p -0.62%FTSE 250 - RisersRegus (RGU) 149.50p +4.18%Spirax-Sarco Engineering (SPX) 2,578.00p +3.00%RIT Capital Partners (RCP) 1,202.00p +2.56%SEGRO (SGRO) 264.60p +2.44%Cobham (COB) 234.20p +2.18%Betfair Group (BET) 702.00p +2.03%Jupiter Fund Management (JUP) 344.60p +1.83%Ashtead Group (AHT) 585.00p +1.74%Rotork (ROR) 2,951.00p +1.58%SIG (SHI) 142.50p +1.50%FTSE 250 - FallersNational Express Group (NEX) 206.90p -10.04%Petropavlovsk (POG) 257.10p -6.34%Hunting (HTG) 889.50p -4.51%Inmarsat (ISAT) 636.50p -4.36%IP Group (IPO) 135.00p -3.23%Balfour Beatty (BBY) 279.30p -2.68%Heritage Oil (HOIL) 192.50p -2.19%International Personal Finance (IPF) 463.90p -2.01%African Barrick Gold (ABG) 241.10p -1.87%Rank Group (RNK) 163.00p -1.69%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.